MM-087 Early, Deep, and Durable Responses, and Low Rates of Cytokine Release Syndrome With REGN5458, a BCMAxCD3 Bispecific Antibody, in a Phase 1/2 First-In-Human Study in Patients With Relapsed/Refractory Multiple Myeloma

医学 耐受性 内科学 养生 细胞因子释放综合征 耐火材料(行星科学) 来那度胺 中性粒细胞减少症 多发性骨髓瘤 不利影响 肿瘤科 外科 毒性 免疫疗法 嵌合抗原受体 癌症 物理 天体生物学
作者
Jeffrey A. Zonder,Joshua Richter,Naresh Bumma,Jason Brayer,James E. Hoffman,William Bensinger,Ka Lung Wu,Linzhi Xu,Dhruti Chokshi,Anita Boyapati,Damien M. Cronier,Yariv Houvras,Karen Rodriguez Lorenc,Glenn S. Kroog,Madhav V. Dhodapkar,Suzanne Lentzsch,Dennis Cooper,Sundar Jagannath
出处
期刊:Clinical Lymphoma, Myeloma & Leukemia [Elsevier BV]
卷期号:22: S406-S407 被引量:3
标识
DOI:10.1016/s2152-2650(22)01591-9
摘要

Despite advances in treatment options, multiple myeloma remains incurable. REGN5458 is a BCMAxCD3 bispecific antibody under investigation in relapsed/refractory multiple myeloma (RRMM): ongoing Phase 1/2 trial (NCT03761108).To describe updated safety, overall response, and response durability in patients treated with REGN5458 in the Phase 1 part.The Phase 1 part follows a modified 3+3 dose-escalation design (4+3).Eligible patients with progressive RRMM, who were double- or triple-refractory, or intolerant to prior lines of systemic therapy, including a proteasome inhibitor, immunomodulatory agent, and anti-CD38 antibody, were included.Sixteen weekly infusions of REGN5458 monotherapy, then every two weeks until disease progression.Primary objectives were to assess safety, tolerability, and occurrence of dose-limiting toxicities of REGN5458, and to determine a recommended Phase 2 dose regimen. The objective response rate by modified International Myeloma Working Group criteria was a key secondary objective.At data cut-off (September 30, 2021), 73 patients were treated with REGN5458 in the dose-escalation cohort, with full doses ranging from 3-800 mg. The median age at enrollment was 64 years (range, 41-81). As per the Revised International Staging System, stages were 1, 2, or 3 in 15.0%, 57.5%, and 23.3% of patients, respectively. Patients had a median of five prior lines of systemic therapy (range, 2-17), with 89% of patients being triple-refractory. The median duration of follow-up was 3.0 months (range, 0.7-22.1). The most common treatment-emergent adverse events (TEAEs) were fatigue (45.2%), cytokine release syndrome (CRS) (38.4%), pyrexia (35.6%), and nausea (32.9%). There were no Grade ≥3 CRS or Grade ≥3 neurotoxicity events, and no treatment discontinuation due to CRS. Grade 3 and 4 TEAEs were reported in 31 (42.5%) and 24 patients (32.9%), respectively. The most common Grade 3/4 TEAEs were hematologic (39.0%). Responses were observed at all dose levels. Amongst patients treated at the 200-800 mg dose levels, the response rate was 75% (n=18/24). The median duration of response was not reached.REGN5458 shows early, deep, and durable responses with a manageable safety profile in triple or greater-refractory patients with RRMM. This study is funded by Regeneron.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
拼搏的潘子完成签到,获得积分10
1秒前
zsj完成签到,获得积分10
2秒前
dolesy发布了新的文献求助10
3秒前
执着烧鹅完成签到 ,获得积分10
3秒前
哈哈哈完成签到,获得积分10
5秒前
yar应助博修采纳,获得10
7秒前
可爱的函函应助博修采纳,获得10
7秒前
MchemG应助博修采纳,获得10
7秒前
酷波er应助博修采纳,获得10
8秒前
时代更迭完成签到 ,获得积分10
8秒前
9秒前
WGOIST完成签到,获得积分10
10秒前
九九完成签到 ,获得积分10
10秒前
李新宇完成签到 ,获得积分10
11秒前
大橙子发布了新的文献求助10
15秒前
库凯伊完成签到,获得积分10
15秒前
duckspy发布了新的文献求助10
16秒前
CodeCraft应助jenny采纳,获得10
18秒前
lhnsisi完成签到,获得积分10
19秒前
jhlz5879完成签到,获得积分10
20秒前
悦耳曼凝完成签到 ,获得积分10
21秒前
文静的紫萱完成签到,获得积分10
21秒前
拼搏的飞薇完成签到,获得积分10
22秒前
曾建完成签到 ,获得积分10
23秒前
pep完成签到 ,获得积分10
24秒前
mufcyang完成签到,获得积分10
28秒前
了晨完成签到 ,获得积分10
29秒前
yi完成签到 ,获得积分10
32秒前
wxnice完成签到,获得积分10
33秒前
量子星尘发布了新的文献求助10
35秒前
星辰大海应助大橙子采纳,获得10
44秒前
44秒前
七QI完成签到 ,获得积分10
45秒前
48秒前
褚香旋完成签到,获得积分10
48秒前
一只狗东西完成签到 ,获得积分10
50秒前
宇老师发布了新的文献求助10
51秒前
52秒前
qiqi发布了新的文献求助30
54秒前
大橙子发布了新的文献求助10
57秒前
高分求助中
【提示信息,请勿应助】关于scihub 10000
Les Mantodea de Guyane: Insecta, Polyneoptera [The Mantids of French Guiana] 3000
徐淮辽南地区新元古代叠层石及生物地层 3000
The Mother of All Tableaux: Order, Equivalence, and Geometry in the Large-scale Structure of Optimality Theory 3000
Handbook of Industrial Diamonds.Vol2 1100
Global Eyelash Assessment scale (GEA) 1000
Picture Books with Same-sex Parented Families: Unintentional Censorship 550
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 4038157
求助须知:如何正确求助?哪些是违规求助? 3575869
关于积分的说明 11373842
捐赠科研通 3305650
什么是DOI,文献DOI怎么找? 1819255
邀请新用户注册赠送积分活动 892655
科研通“疑难数据库(出版商)”最低求助积分说明 815022